Glucagen Kit (Glucagon)

Glucagen Kit is indicated for the acute treatment of conditions that cause dangerously low blood glucose levels.

• Severe hypoglycemia in patients with diabetes when oral glucose is not feasible.
• Insulin overdose resulting in prolonged hypoglycemia.
• Emergency reversal of hypoglycemia in unconscious or unable‑to‑swallow patients.
• Situations requiring rapid restoration of blood glucose during surgical or procedural sedation.
• As a rescue medication for children with type 1 diabetes experiencing severe hypoglycemia.

Adverse reactions to glucagon are generally infrequent, but they can be categorized by frequency and severity.

Common

• Nausea or vomiting, typically transient and self‑limited.
• Flushing, warmth, or feeling of heat at the injection site.
• Headache, mild and usually resolves without treatment.
• Pain, redness, or swelling at the injection site.
• Dizziness or light‑headedness shortly after injection.

Serious

• Allergic reactions, including rash, urticaria, or anaphylaxis, requiring immediate medical attention.
• Marked hypotension or cardiovascular collapse, especially with rapid intravenous administration.
• Significant hyperglycemia if an excessive glucagon dose is given, potentially leading to osmotic diuresis.

When using Glucagen Kit, healthcare providers should observe several precautions to ensure safe and effective administration.

• Verify patient identity and confirm indication before injection.
• Assess for known hypersensitivity to glucagon or any kit components.
• Use appropriate dose and route; avoid rapid intravenous bolus unless specifically indicated.
• Monitor blood glucose levels before and after administration to prevent over‑correction.
• Caution in patients with pheochromocytoma, adrenal insufficiency, or recent myocardial infarction.
• Do not administer intramuscularly in the gluteal region of infants due to risk of nerve injury.
• Store the kit according to manufacturer instructions, protecting it from light and extreme temperatures.

Glucagon may interact with other medications; awareness of these interactions helps avoid reduced efficacy or adverse events.

Avoid

• Concurrent use of beta‑blockers, which can blunt the hyperglycemic response to glucagon.
• High‑dose insulin therapy that may overwhelm glucagon’s effect, leading to persistent hypoglycemia.

Use with caution

• Catecholamines (e.g., epinephrine) may potentiate cardiovascular effects of glucagon.
• Oral hypoglycemic agents, especially sulfonylureas, may increase risk of recurrent hypoglycemia after glucagon administration.
• Diuretics that predispose to electrolyte imbalance, potentially affecting glucagon’s action.
• Anticholinergic drugs that may reduce gastrointestinal motility, influencing glucose absorption after glucagon.